MetaCap

Vor Biopharma (VOR) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.18 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VOR-1.18%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
VOR-1.18%WWB-14.79%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VOR versus WWB key metrics
MetricVORWWB
Share price$19.19$24.29
Market cap$1.18B$1.45B
1-day change+3.62%+1.15%
YTD return+46.71%—
1-year return+157.58%—
5-year return-92.00%—
P/E ratio (TTM)0.06—
EPS (TTM)$300.56$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-695.98M—
52-week high$26.00$33.99
52-week low$7.21$18.35
Distance from 52-week high-26.19%-28.55%
Analyst consensusstrong_buy—
Avg. price target upside+103.23%—
Average volume945.67K434.33K
Shares outstanding61.43M59.58M
Employees7633
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Vor Biopharma

VOR stock →

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

VOR vs WWB FAQ

Which is bigger, Vor Biopharma or Windward Bio Group?

Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.18B for Vor Biopharma (VOR).

Are Vor Biopharma and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons